Simpson Thacher Represents Alvogen and Pamplona in the Sale of a Controlling Stake in Alvogen



Brian M. Steinhardt Brian M. Steinhardt
Brian Gluck Brian Gluck
Michael T. Holick Michael T. Holick
Clare Gaskell Clare Gaskell
Andrew Blau Andrew Blau
+1

The Firm represented Alvogen and Pamplona Capital Management (“Pamplona”) in connection with Pamplona’s sale of a controlling stake in Alvogen to a consortium of investors led by CVC Capital Partners.

Alvogen is an international, privately owned pharmaceuticals company focused on developing, manufacturing and selling generic, brand, over-the-counter brands and biosimilar products.

The Simpson Thacher team included Michael T. Holick, Michael Guo and Michael Chao (M&A – New York); Clare Gaskell and Charles Leeming (M&A – London); Brian Steinhardt and Brian Gluck (Credit); Michael Naughton and Philip Mirrer-Singer (Competition); Devin Heckman (Tax); Brian Robbins, Andrew Blau and Patricia Adams (Executive Compensation and Employee Benefits); Noah Leibowitz and Genevieve Dorment (Intellectual Property); and Adeeb Fadil and Louise Kruger (Environmental).